Hematology/Oncology

Top Story

FDA approves Keytruda for certain gastric cancers

FDA approves Keytruda for certain gastric cancers
September 22, 2017

The FDA today approved pembrolizumab for the treatment of patients with recurrent locally advanced or metastatic gastric or gastroesophageal junction adenocarcinoma, according to a press release from the manufacturer.

The approval applies to use of pembrolizumab (Keytruda, Merck) — a humanized monoclonal antibody that blocks the interaction of PD-1 and its ligands — among patients whose tumors express PD-L1 and who experienced disease progression on or after two or more prior lines of fluoropyrimidine- and platinum-based chemotherapy or HER-2/neu-targeted therapy.

Video

Baseball star who survived melanoma ‘suffering’ from lack of sunscreen use

September 22, 2017
Mike Schmidt, a former member of the Philadelphia Phillies widely considered to be the greatest third baseman in Major League Baseball history, received a
In the Journals Plus

Bevacizumab extends survival in advanced cervical cancer

September 22, 2017
The addition of bevacizumab to chemotherapy continued to show significant survival benefits in women with advanced cervical cancer, according to final analysis of a…

Gurman says, ‘Our voice is their voice’ in explaining the importance of physician advocacy

September 22, 2017
At a time when the state of health care is in flux, it is critical that physicians engage in the national debate by telling their stories and those of their patients to…

Five important updates in sickle cell disease

September 22, 2017
National Sickle Cell Awareness Month — observed in September — draws attention to the collection of inherited blood disorders that affect up to 100,000…
More Headlines »
CME

Bridging the Gap from Knowledge to Practice in CRPC

This activity is supported by educational funding provided by AbbVie Inc.; Astellas Scientific and Medical Affairs, Inc. and Medivation; and Sanofi US.

The selection of therapy for patients with castration-resistant prostate cancer (CRPC) remains challenging. Review…
More »
Video
Meeting News

VIDEO: Additional treatment with ALK inhibitor after progression shows promise in non-small cell lung cancer

September 18, 2017
More »
Resource Centers
European Society for Medical Oncology Congress

European Society for Medical Oncology Congress

CME

Hot Topics in Metastatic Breast Cancer Management: Clinical Advances with CDK4/6 Inhibitors

This activity is supported by an educational grant from Novartis Pharmaceuticals Corporation.

While the mortality rates for advanced or metastatic breast cancer (MBC) have steadily decreased, in part due to…
More »
Current Issues
View the Current Issue
HemOnc Today
Advertisement
Advertisement